Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

Neoantigen-Targeted Dendritic Cell Vaccination in Lung Cancer Patients Induces Long-Lived T Cells Exhibiting the Full Differentiation Spectrum

April 15, 2024

[Cell Reports] Investigators presented the results of a Phase I clinical trial in which a dendritic cell vaccine targeting patient-individual neoantigens is evaluated in patients with resected non-small cell lung cancer.

Tissue-Specific Nonheritable Influences Drive Endometrial Immune System Variation

April 11, 2024

[Science Immunology] To assess uterine immune system variation, investigators performed a system-level analysis of endometrial and peripheral blood immune cells in monozygotic twins.

Neuromedin-U Mediates Rapid Activation of Airway Group 2 Innate Lymphoid Cells in Mild Asthma

April 11, 2024

[American Journal Of Respiratory And Critical Care Medicine] Researchers investigated the effect of NMU/NMUR1 axis on early activation of group 2 innate lymphoid cells in asthma. Mild asthmatics were enrolled in a diluent-controlled, allergen-inhalation challenge study.

Essential Pharma Acquires Renaissance Pharma Ltd with Its Clinical Stage Immunotherapy for the Treatment of High-Risk Neuroblastoma

April 10, 2024

[Essential Pharma] Essential Pharma announced that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance Pharma is a clinical stage pharmaceutical company focused on the development of life changing therapies in pediatric rare disease.

Immunological Aspects of Central Neurodegeneration

April 9, 2024

[Cell Discovery] Scientists critically discuss immunological mechanisms of central neurodegeneration and propose potential strategies to correct neurodegeneration-associated immunological dysfunction with therapeutic purposes.

Immune-Mediated Necrotizing Myopathies: Current Landscape

April 9, 2024

[Current Neurology And Neuroscience Reports] Scientists synthesized current knowledge on Iimune-mediated necrotizing myopathy emphasizing its distinct clinical features and challenging management. The evolving understanding of IMNM underscores the need for a comprehensive diagnostic approach that utilizes a growing range of modalities.

Congratulations to the Immunobiology F31 Awardees!

April 9, 2024

[Yale School of Medicine] Yale School of Medicine annanounced announce that two Immunobiology PhD students, Tomomi Yoshida and Sarah Ohashi were recently awarded the prestigious Ruth L. Kirschstein Predoctoral Individual National Research Service Awards from the National Institutes of Health.

Announcing 2024 FASEB Excellence in Science Awards

April 9, 2024

[FASEB] The Federation of American Societies for Experimental Biology (FASEB) announced the recipients of its 2024 Excellence in Science Awards. An experimental pathologist and immunologist, Pilar Alcaide of Tufts University School of Medicine is the recipient of the Mid-Career Investigator Award.

A Lipid Atlas of Human and Mouse Immune Cells Provides Insights Into Ferroptosis Susceptibility

April 8, 2024

[Nature Cell Biology] Using this resource, researchers showed that immune cells have unique lipidomic signatures and that processes such as activation, maturation, and development impact immune cell lipid composition.

Stroma-Infiltrating T Cell Spatiotypes Define Immunotherapy Outcomes in Adolescent and Young Adult Patients with Melanoma

April 8, 2024

[Nature Communications] The authors characterized the immunogenomic profile and spatial architecture of the tumor microenvironment in adolescent and young adult (AYA) and older adult patients with melanoma, to determine the AYA-specific features associated with immune checkpoint inhibitors treatment outcomes.

Single-Cell RNA-Sequencing of Virus-Specific Cellular Immune Responses in Chronic Hepatitis B Patients

April 8, 2024

[Scientific Data] Researchers created a single-cell RNA-sequencing dataset of HBV immune responses in patients to contribute to a better understanding of the dysregulated immunity.

Personalized Neoantigen Vaccine and Pembrolizumab in Advanced Hepatocellular Carcinoma: A Phase I/II Trial

April 8, 2024

[Nature Medicine] The authors present results from a single-arm, open-label, Phase I/II study of a DNA plasmid PTCV encoding up to 40 neoantigens coadministered with plasmid-encoded interleukin-12 plus pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with a multityrosine kinase inhibitor.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.